Afterload reduction may halt and beta-adrenergic blockade may worsen progression of left ventricular dysfunction in patients with chronic compensated mitral regurgitation: A retrospective cohort study

Angiology

Volumn 58, Issue 2, 2007, Pages 196-202

  Oh, Stacie H ^a   Meyers, David G ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART AFTERLOAD; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; MITRAL VALVE REGURGITATION; MULTIVARIATE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MITRAL VALVE INSUFFICIENCY; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34247623222     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707300357     Document Type: Article

References (25)

1. Harshaw CW, Grossman W., Munro AB,, et al. Reduced systemic vascular resistance as therapy for severe mitral regurgitation of valvular origin. Ann Intern Med 83: 312-316, 1975.
2. ACC/AHA guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32: 486-588, 1998.
3. Otto CM: Evaluation and management of chronic mitral regurgitation. N Engl J Med 345: 740-746, 2001.
4. W isenbaugh T, Spann J., Carabello B.: Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. J Am Coll Cardiol 3: 916-923, 1984.
5. Levine HJ, Gaasch W.H.: Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 73: 978-981, 1996.
6. Greenberg BH, DeMots H., Murphy E.,, et al. Arterial dilators in mitral regurgitation: Effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 65: 181-187, 1982.
7. W isenbaugh T., Sinovich V., Dullabh A.,, et al. Six-month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 3: 197-204, 1994.
8. Marcotte F., Honos GN, W alling AD,, et al. Effect of angiotensin converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol 13: 479-485, 1997.
9. Tischler MD, Rowan M., LeW inter MM: Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 82: 242-245, 1998.
10. Ronen A., Aurigemma GP, Lucey G.,, et al. Serial changes in the left ventricular and left atrial size and function in mitral regurgitation due to mitral valve prolapse (abstract). Circulation 10 (suppl I). 146, 1999.
11. Enriquez-Sarano M., Basmadjian AJ, Rossi A.,, et al. Progression of mitral regurgitation: A prospective Doppler echocardiographic study. J Am Coll Cardiol 34: 1137-1144, 1999.
12. Enriquez-Sarano M., Tajik AJ, Schaff HV,, et al. Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 90: 830-837, 1994.
13. Gaasch W.H., Aurigemma GP: Inhibition of the reninangiotensin system and the left ventricular adaptation to mitral regurgitation. J Am Coll Cardiol 39: 1380-1383, 2002.
14. Sakagoshi N., Nakano S., Taniguchi K.,, et al. Relation between myocardial beta-adrenergic receptor and left ventricular function in patients with left ventricular volume overload due to chronic mitral regurgitation with or without aortic regurgitation. Am J Cardiol 68: 81-84, 1991.
15. Dzimiri N., Moorji A.: Beta-adrenergic density in patients with left-sided valvular regurgitation. Fundam Clin Pharmacol 10: 547-553, 1996.
16. Lowes BD, Gill EA, Abraham W.T.,, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83: 1201-1205, 1999.
17. Nemoto S., Hamawaki M., De Freitas G.,, et al. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol 40: 149-154, 2002.
18. Zoghbi W.A., Enriquez-Sarano M., Foster E.,, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16: 777-802, 2003.
19. Goodman DJ, Rossen RM, Holloway EL,, et al. Effect of nitroprusside on left ventricular dynamics in mitral regurgitation. Circulation 50: 1025-1032, 1974.
20. Schon HR, Schroter G., Blomer H.,, et al. Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation. Am J Cardiol 73: 785-791, 1994.
21. Eichorn EJ, Bristow MR: Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 94: 2285-2296, 1996.
22. Cohen JN, Pfeffer MA, Rouleau J.,, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5: 659-657, 2003.
23. Borer JS, Bonow RO: Contemporary approach to aortic and mitral regurgitation. Circulation 108: 2432-2438, 2003.
24. Metra M., Giubbini R., Nodari S.,, et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol vs carvedilol. Circulation 102: 546-551, 2000.
25. Cleland Jgf, Pennell DJ, Ray SG,, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomized, controlled trial. Lancet 362: 14-21, 2003.